Kepler Capital Keeps Their Buy Rating on Bayer (0P6S)
In a report released on February 5, Christian Faitz from Kepler Capital maintained a Buy rating on Bayer, with a price target of €53.00. The company’s shares closed last Friday at €44.82.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Faitz is a 4-star analyst with an average return of 6.9% and a 50.91% success rate. Faitz covers the Basic Materials sector, focusing on stocks such as Wacker Chemie AG, K+S Aktiengesellschaft, and Johnson Matthey.
In addition to Kepler Capital , Bayer also received a Buy from Goldman Sachs’s James Quigley in a report issued on February 6. However, on the same day, UBS maintained a Hold rating on Bayer (LSE: 0P6S).
The company has a one-year high of €46.74 and a one-year low of €18.38. Currently, Bayer has an average volume of 3.65M.
Read More on GB:0P6S:
Disclaimer & DisclosureReport an Issue
- Bristol Myers price target raised to $68 from $64 at BofA
- Truist incrementally positive on Bristol Myers after Bayer asundexian data
- Bayer says Asundexian showed 26% reduction in stroke in Phase III study
- Bayer investing over C$45M to build canola research, development facility
- Bayer, Vanderbilt University Medical Center enter five-year collaboration
